Ziopharm Oncology, Inc. (NASDAQ: ZIOP), is collaborating with Aldevron to secure rapid neoGMP® plasmid DNA manufacturing for Ziopharm's Sleeping Beauty construct to express TCRs for treatment of solid tumors.
Ziopharm will receive neoGMP plasmid DNA for T cell therapeutics targeting solid tumors. The innovative approach is achieved by expressing T cell receptors using the Sleeping Beauty non-viral gene transfer system.
The rapid production of Aldevron's neoGMP® service is paramount to the successful delivery of personalized cancer treatment.
The agreement represents an ongoing dedication to deliver best-in-class personalized therapeutics to patients in need.